Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 4/20 | 0.89 |
| ▸ | BACE1 | P56817 | 9/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | CTSB | P07858 | 5/20 | 0.62 |
| ▸ | CTSL | P07711 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.60 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.57 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1646523 | 1.00 | APP (0.89) | APPBACE1MAPTCTSBCTSL | |
| SCHEMBL9234911 | 0.94 | APP (1.00) | APPBACE1MAPTCTSBCTSL | |
| SCHEMBL9234919 | 0.94 | APP (1.00) | APPBACE1MAPTCTSBCTSL | |
| SCHEMBL3204189 | 0.87 | APP (0.86) | APPBACE1MAPTCTSBCAPN1 | |
| SCHEMBL3204195 | 0.87 | APP (0.86) | APPBACE1MAPTCTSBCAPN1 | |
| SCHEMBL1646604 | 0.86 | APP (0.84) | APPBACE1MAPTCTSBCTSL | |
| SCHEMBL1646600 | 0.86 | APP (0.84) | APPBACE1MAPTCTSBCTSL | |
| SCHEMBL1647560 | 0.85 | APP (0.82) | APPBACE1MAPTCTSBCTSL | |
| SCHEMBL1647558 | 0.85 | APP (0.82) | APPBACE1MAPTCTSBCTSL | |
| SCHEMBL3200561 | 0.83 | BACE1 (1.00) | APPBACE1MAPTTDP1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8552220-B2 | Therapeutic agent for Alzheimer's disease | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20110082295-A1 | NOVEL CURCUMIN DERIVATIVE | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-04-07 | — | — | US | disclosed |
| EP-2305629-A1 | THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | Tokyo Institute of Technology (JP) | 2011-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082295-A1 | NOVEL CURCUMIN DERIVATIVE | BACE1, APP, BACE2 | APP 2/4885BACE1 1/4885MAPT 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.